Fraser Glickman

Title: Fraser Glickman – Innovator in Pharmaceutical Chemistry

Introduction

Fraser Glickman is a notable inventor based in Basel, Switzerland, recognized for his contributions to the field of pharmaceutical chemistry. With two patents to his name, he has made significant strides in developing compounds that target crucial biological pathways.

Latest Patents

Glickman's latest patents include innovative formulations that address important medical needs. One of his patents focuses on isothiourea derivatives of imidazo[2,1-b]thiazoles and their 5,6-dihydro derivatives, which are useful as CXCR4 chemokine receptor inhibitors. This invention not only details the structures of these derivatives but also provides processes for their production. Another significant patent entails ergoline derivatives that contain a variety of substitutions and modifications, aimed at preventing or treating disorders mediated by interactions between chemokine receptors and their ligands.

Career Highlights

Glickman works with Novartis AG, a leading global healthcare company known for its focus on innovation and research in pharmaceuticals. His work at Novartis has positioned him at the forefront of pharmaceutical development, contributing to essential breakthroughs that impact patient treatment options.

Collaborations

Throughout his career, Fraser Glickman has collaborated with esteemed colleagues such as Markus Streiff and Gebhard Thoma. These partnerships have fostered an environment of innovation and creativity, enhancing the research efforts within their projects and leading to successful patent applications.

Conclusion

Fraser Glickman's contributions to the field of pharmaceutical chemistry exemplify the innovative spirit that drives advancements in medical science. His patents not only highlight his expertise but also offer promising avenues for the treatment of various diseases through targeted therapeutic approaches.